Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.16 EUR
Change Today +0.026 / 2.30%
Volume 0.0
TEHN On Other Exchanges
As of 2:15 AM 05/7/15 All times are local (Market data is delayed by at least 15 minutes).

peregrine pharmaceuticals (TEHN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/9/15 - €1.51
52 Week Low
10/13/14 - €0.99
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

peregrine pharmaceuticals (TEHN) Related Businessweek News

No Related Businessweek News Found

peregrine pharmaceuticals (TEHN) Details

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also evaluating its lead molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of various solid tumor types. In addition, it provides contract manufacturing services ranging from cell line development to commercial current good manufacturing practice biomanufacturing to third-party clients. The company has various license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

180 Employees
Last Reported Date: 07/14/14
Founded in 1981

peregrine pharmaceuticals (TEHN) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $557.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $423.6K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $393.8K
Vice President of Intellectual Property
Total Annual Compensation: $364.7K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: $338.0K
Compensation as of Fiscal Year 2014.

peregrine pharmaceuticals (TEHN) Key Developments

Peregrine Pharmaceuticals Announces Encouraging Data from Melanoma and Breast Cancer Studies

Peregrine Pharmaceuticals, Inc. has announced data from preclinical studies which demonstrated that the combination of phosphatidylserine, or PS, blockade with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors reduced tumor immune system blockade and enhanced tumor specific immune responses in models of melanoma and breast cancer. Peregrine's lead PS-blocking antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) in a Phase III clinical trial named Sunrise. The result were synergistic anti-tumor effects in established melanoma and breast cancers. The consistency of the data generated from preclinical experiments, and, more recently, in clinical translational studies is impressive. Both combinations showed significantly superior tumor growth inhibition over single treatment, with many subjects achieving complete tumor regressions. The combination treatment showed significantly greater total and functional tumor-infiltrating CD8+ T, more IL-2- and interferon gamma (IFN gamma)-producing splenic T cells, and lower number of splenic myeloid derived suppressor cells myeloid-derived suppressor cells (MDSCs) than did single treatment. In addition, the ratio of M2 to M1 macrophages in the tumor was significantly lower in the combination treatment than that in single treatment. Finally, no toxicity was observed in any of the treatment groups following multiple treatment doses.

Peregrine Pharmaceuticals, Inc. Announces Encouraging Data from Non-Small Cell Lung Cancer Study

Peregrine Pharmaceuticals, Inc. has announced encouraging data from clinical translational studies with its phosphatidylserine, or PS, targeting immunotherapy, bavituximab, in patients with non-small cell lung cancer, or NSCLC. Initial data from a pilot study of clinical translational ex vivo cultures show that bavituximab, both alone and with docetaxel, elicits evidence of a tumor-specific immune response in patients with human adenocarcinoma of the lung and that bavituximab exhibits an impact on tumors with negative PD-L1 expression. Bavituximab is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial. Translational findings of a cytokine profile that reflects an immune response following either bavituximab single-agent or combination treatment are encouraging. Furthermore, these preliminary translational data show that tumors with negative PD-L1 expression and low levels of PD-1 expression on CD8+ tumor infiltrating T cells showed immune response to bavituximab treatment ex vivo.

Peregrine Pharmaceuticals, Inc. Announces Bavituximab Phase I Data Published in the Peer-Reviewed Journal Cancer Medicine in Advanced Metastatic Breast Cancer

Peregrine Pharmaceuticals, Inc. announced the peer-reviewed publication of clinical data from a Phase I investigator-sponsored trial evaluating the company's lead investigational immunotherapy bavituximab plus paclitaxel therapy in patients with HER2-negative metastatic breast cancer. The manuscript details the results of the Phase I trial showing that the combination produced an objective tumor response in 85% of patients, including 15% of these patients achieving a complete response, measured in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria. In the online released manuscript, researchers at the University of Arizona Medical Center led by Alison Stopeck, M.D. enrolled 14 patients with metastatic breast cancer (MBC) and while all were evaluable for toxicity, 13 were evaluable for response and progression free survival (PFS). These patients with HER2-negative MBC were treated with paclitaxel (80 mg/m2) weekly for three weeks of each four-week cycle and bavituximab (3 mg/kg) administered weekly beginning on day 15 after two weekly doses of paclitaxel. Results from 13 evaluable patients showed that 11 patients (85%) achieved an objective response, including two patients (15%) that achieved a complete response (CR), 9 patients with partial responses (PR) and 2 patients with progressive disease (PD). Median PFS for the combination of bavituximab with weekly paclitaxel was 7.3 months. In addition, the combination of bavituximab and paclitaxel was safe and well-tolerated with the majority of grade 1 or 2 adverse events being paclitaxel related. Approximately half of these patients were classified as "triple negative," a traditionally difficult-to-treat patient population. In addition, treatment with bavituximab reduced circulating PS-expressing microparticles (exosomes) which are immunosuppressive.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEHN:GR €1.16 EUR +0.026

TEHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $19.57 USD -0.19
Genocea Biosciences Inc $9.81 USD -0.17
GenVec Inc $2.33 USD +0.03
Inovio Pharmaceuticals Inc $8.09 USD -0.18
Progenics Pharmaceuticals Inc $5.53 USD +0.51
View Industry Companies

Industry Analysis


Industry Average

Valuation TEHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.8x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PEREGRINE PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at